Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243631 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02243631: Completed Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT02243631 is a Early Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02243631, a Early Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.
Interventions
- DRUG Probenecid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-10-15 |
| Est. Completion | 2021-04-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02243631
The ClinicalTrials.gov registry entry for NCT02243631 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Probenecid is the first listed.
NCT02243631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02243631 about?
NCT02243631 is a clinical study titled "Effect of Probenecid on Synovial Fluid ATP Levels in CPPD". This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from...
What is the current status of trial NCT02243631?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2014-10-15. Estimated completion is 2021-04-08.
What interventions are being tested in trial NCT02243631?
The interventions under investigation include: Probenecid (DRUG).
Who is sponsoring clinical trial NCT02243631?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.